Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. - Wikidata - wikimedia - TriplyDB

Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study.

Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study.

http://www.wikidata.org/entity/Q33562586

about

The role of aflibercept in the management of diabetic macular edema Pathophysiology of diabetic retinopathy Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy Diabetic macular edema: New promising therapies.Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy Diabetic macular edema: new trends in management.Current treatments in diabetic macular oedema: systematic review and meta-analysis The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy.Diabetic retinopathy - An update.Tumor necrosis factor inhibitors - state of knowledge.Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy?Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes.Macular structure and function and the development of retinopathy in diabetes.Emerging drugs for managing kidney disease in patients with diabetes.Targeting inflammation in diabetic kidney disease: early clinical trials.Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy.Diabetic retinopathy: current understanding, mechanisms, and treatment strategies Angiogenic Factors and Cytokines in Diabetic Retinopathy.Infliximab relieves blood retinal barrier breakdown through the p38 MAPK pathway in a diabetic rat model.Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy.Potential Interplay between Hyperosmolarity and Inflammation on Retinal Pigmented Epithelium in Pathogenesis of Diabetic Retinopathy.Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy.Spectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapy.Modulation of three key innate immune pathways for the most common retinal degenerative diseases

P2860

Q26798348-0592B607-1BB2-4649-9702-DD61261B0252 Q26865897-E99CC35B-057C-4ECE-8355-D62E28FEF60F Q28066675-5A155E4F-ED5A-45DD-9E4F-ECF8946D0B35 Q28078199-0C804274-7642-49E7-BBA4-F6A54E5C5479 Q30415630-76B7BB5D-01DF-4662-9EE4-7E39A026A501 Q34011852-A7BD348E-07F5-48D8-B35F-2DA85B261BFD Q34091784-A58C40C3-E947-4422-8BE6-9351A124C019 Q34606190-1FB96B6C-B8FB-4488-88A6-6D80BD3E12F0 Q34645612-95670FF0-F917-485A-96AE-F72ADAF65F66 Q34957902-622B6195-A6AE-4549-9D08-6F41FB2E36CB Q34974335-22A1CE19-9FA0-4289-B548-AF4C6E3DA3D2 Q36052279-8476F1DA-C43C-4CBC-A054-E9CA3200A56F Q36174993-D59D6C78-1FF7-4132-B9ED-626F7A0D7138 Q36766273-C29995FF-9104-449E-B390-D37496660542 Q36867626-27E7A775-FBAC-4D62-88BE-9CD642317492 Q37095335-6385AFAD-9DBC-4D6D-BDC5-C5DE417776C2 Q37950419-66A230EB-5404-45D5-9FF3-D79865390F9E Q38075029-3DB366FE-86C6-4505-9DAF-802112302D79 Q38857166-8BEADC15-2354-438A-89E3-D4B7C9204B51 Q39103248-A12A1F3E-4A21-469E-84FA-ABCA94CA1538 Q39445950-D4E1CC81-C49A-4743-B85C-5D09FAD027E4 Q41883466-CF78EAB6-A837-409C-A635-19CA13EF8BD0 Q47104993-B119BA58-BDA1-4571-A03B-18765B9A1419 Q47123777-E2415400-7762-45FB-902C-0C61CF918CA1 Q52609620-AA99DC13-F3AF-4BBE-86DB-E928280EF7D7 Q53913493-32C88A5A-402F-47F1-92E3-016152B0122D Q54537601-C9B3A662-0321-4A9E-A423-5525B5ADB255 Q58728893-120101CF-619A-490E-BFAF-C0A1FF656972

P2860

Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study.

http://www.wikidata.org/entity/Q33562586

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@ast

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@en

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@nl

type

label

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@ast

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@en

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@nl

prefLabel

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@ast

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@en

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@nl

P1433

Q33562586-84C248DC-4730-44D0-80D1-3C26F92BE70A

P1476

Q33562586-28AB1E2C-78A1-487E-ADBE-54439391DD62

P2093

Q33562586-294844E3-F912-4A0D-B327-12A6AA4E6B8F

Q33562586-5686F44B-FD3D-4EE2-A5ED-04329532F108

Q33562586-7D5AF5BA-E1C2-4790-BF9C-6269214C0AA9

Q33562586-88D94F5A-426A-4F9C-8570-40DA237B6DD9

Q33562586-8AC0DEFB-F74B-40D5-81C2-AD5FDADD1B7F

Q33562586-9531635C-B5D3-482D-8CA7-3FF35D997A1C

Q33562586-A6B2667B-65B5-4C47-95BE-539F236029F2

Q33562586-BDB485D6-D862-4D1B-A817-A366B874A557

Q33562586-E98033AE-3F48-4356-B850-9454D36B522D

P2860

Q33562586-27890BC7-7248-455A-A9A3-39A6E6504124

Q33562586-2BC5A5EA-193C-4D04-BF08-1DF42C2100B4

Q33562586-305C7317-624D-4B1A-9769-94CA30FAD7A1

Q33562586-3979E2A2-6EB3-40ED-A649-3B4F7CC337B6

Q33562586-3BBBB37B-62F2-4C87-A763-3CCBB92B06BE

Q33562586-43617C37-D9C1-4DCA-862E-ABE5CDEDFCAA

Q33562586-493B76A5-BA3D-48F6-9A03-C62E59736D31

Q33562586-5501BDBB-3D26-4761-AAA8-E05C486E6DBE

Q33562586-60B2CDDE-4ACF-405D-8A6D-BF3FDC981060

Q33562586-6839052D-63C5-4183-9193-7D62E181B02B

P304

Q33562586-41B25BAE-9B42-4ADA-9684-397A9ABBEBB5

P31

Q33562586-DF8D7997-8BBB-4EB1-935D-104F558CF37E

P356

Q33562586-67BD422F-01AE-4CB8-B7E5-FC5CBF1B31AE

P407

Q33562586-2FD09291-C869-499C-ABC5-0A36B3584CC0

P433

Q33562586-8C6A701A-CA42-4C7C-99DB-62E2ECD7694C

P478

Q33562586-65A9694E-9B1C-438F-BCF7-64058BCEEAF1

P50

Q33562586-D08C3EC4-0DBC-48A8-8ADE-295D731D2598

P577

Q33562586-83A59833-0EF4-43E1-BF64-C5D9452B522C

P5875

Q33562586-73BE7280-FD35-4750-BCEA-F85E4FA0DB0E

P698

Q33562586-D3A1EA78-4906-4F5A-8E14-8C885238C406

P921

Q33562586-0883A9EB-6F8C-4159-9C85-A443153E4D01

Q33562586-BE3E4FD4-67E7-42AD-ABD2-8CFCD58F3303

P932

Q33562586-4A81A9EB-B906-4BC0-9EDA-0E330A76B4FC

P356

P1433

P1476

Infliximab for diabetic macula ...... led, crossover, 32-week study.

@en

P2093

Erifili Hatziagelaki

http://www.w3.org/2001/XMLSchema#string

Evi Delicha

http://www.w3.org/2001/XMLSchema#string

George Theodossiadis

http://www.w3.org/2001/XMLSchema#string

Ioannis Emfietzoglou

http://www.w3.org/2001/XMLSchema#string

Kleopatra Alexiadou

http://www.w3.org/2001/XMLSchema#string

Nicholas Tentolouris

http://www.w3.org/2001/XMLSchema#string

Panayiotis G Theodossiadis

http://www.w3.org/2001/XMLSchema#string

Petros P Sfikakis

http://www.w3.org/2001/XMLSchema#string

Vlassis Grigoropoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Intravitreal steroids for macular edema in diabetes

Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.

Interventions for diabetic macular oedema: a systematic review of the literature.

Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables

Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review.

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Tumor necrosis factor receptor and Fas signaling mechanisms.

The pathogenesis of edema in diabetic maculopathy.

Macular edema. A complication of diabetic retinopathy.

P304

1523-1528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-2372

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Christina G Katsiari

P577

2010-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43299133

http://www.w3.org/2001/XMLSchema#string

P698

20413522

http://www.w3.org/2001/XMLSchema#string

P921

Light Coagulation

P932

2890353

http://www.w3.org/2001/XMLSchema#string